Subinhibitory Concentrations of Prim-O-Glucosylcimifugin Decrease the Expression of Alpha-Hemolysin in Staphylococcus aureus (USA300). (19th July 2018)

• Record Type: Journal Article
• Authors: Ping, Ouyang; Ruixue, Yang; Jiaqiang, Deng; Kaiyu, Wang; Jing, Fang; Yi, Geng; Xiaoli, Huang; Defang, Chen; Weimin, Lai; Li, Tang; Lizi, Yin
• Other Names: Rios José L. Academic Editor.
• Is Part Of: Evidence-based complementary and alternative medicine. Volume 2018(2018)
• Publication Date: 2018-07-19
• Subjects: Alternative medicine -- Periodicals; 615.505
• DOI: 10.1155/2018/7579808
• Languages: English
• ISSNs: 1741-427X

Abstract

Abstract : Staphylococcus aureus (S. aureus), an important opportunistic pathogen in human and animal, causes a series of diseases in the impairing of immunity of host and even then death. Alpha-hemolysin (Hla), a primary virulence factor, plays a major role in the pathogenic progress of S. aureus, especially in pneumonia. Prim-O-glucosylcimifugin (POG), a nature chromone compound, is an active ingredient in many Chinese Medicines. In this study, POG investigated the inhibitory effect of the secretion of Hla in S. aureus strain USA300 at the subinhibitory concentrations. The hemolysis assays and western blotting assays showed that POG can decrease the production of Hla in the USA300 growth cell cultures in a dose-dependent manner. The results of RT-PCR revealed that reduction of Hla was related to inhibit the transcription of hla and RNAIII . In the cells experiment, POG was proved to protect A549 cells from Hla-medicated injury. In conclusion, POG was shown the capacity of decreased the production of S. aureus Hla. POG can be developed as a candidate agent to treat S. aureus infections against Hla.